TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Alcohol Pharmacotherapy for HIV+ Prisoners With Alcohol Dependence and Problem Drinking
Brief Summary: This is a randomized controlled trial of injectable intramuscular naltrexone (XR-NTX) versus intramuscular placebo among HIV-infected prisoners meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for alcohol dependence or problem drinking, who are transitioning to the community and seeking treatment to prevent relapse to alcohol use. We hypothesize that extended release naltrexone (XR-NTX) will result in improved HIV outcomes (lower log10 HIV-1RNA levels and higher CD4 count) as well as improved alcohol treatment outcomes, and reduced drug/sex HIV related risk behaviors and decreased rates of reincarceration.


Options:
A: Inclusion Criteria:

* female parolees or probationers enrolled in a six-month program at one of two residential treatment (RDT) programs,
* convicted for a drug crime, and
* reported homeless on their RDT entry form

Exclusion Criteria:

* female parolees or probationers not currently enrolled in a six-month program at one of two residential treatment (RDT) programs,
* not recently convicted for a drug crime, and
* not reported homeless on their RDT entry form
B: Inclusion Criteria:The study population will be drawn from all adult patients at participating compulsory rehabilitation facilities who:

1. have been incarcerated for at least one year and would have been eligible for MMT at the time of incarceration,
2. have at least 1 month remaining before release,
3. met the DSM-IV criteria for heroin dependence at the time of incarceration,
4. are willing to enroll in methadone maintenance treatment, and
5. are Shanghai residents who reside in the areas of Shanghai targeted by the study.

Exclusion Criteria: Individuals diagnosed with severe mental illness will not be eligible to participate.
C: Inclusion Criteria:

1. HIV+
2. Inmates returning to New Haven or Hartford
3. Meets criteria for alcohol dependence (using Diagnostic and Statistical Manual IV) or problem drinking (using Alcohol Use Disorder Identification Test-AUDIT)
4. Gives informed consent
5. English or Spanish speaker
6. \> 18 yrs

Exclusion Criteria:

1. On opiate pain medication or expressing need for them
2. Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) \> 5x the upper limit of normal
3. Evidence of Child's Pugh Class C cirrhosis
4. Pending felony charges
5. Pregnant or unwilling to take contraceptive measures
6. Subject is part of another pharmacological research study
D: Inclusion Criteria:

* Women aged 18-64 years
* Patients at the health care site
* Able to participate in English
* Able to separate from accompanying person(s)

Exclusion Criteria:

* Too ill to participate
* Unable to separate from accompanying person(s)
* Unable to speak, read, or write English

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Phase 4 12-week, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Safety And Efficacy Of Varenicline Tartrate (CP-526,555) 1mg BID For Smoking Cessation In Subjects With Depression
Brief Summary: Patients with depression tend to have a higher prevalence of smoking as well as increased severity of nicotine dependence. Phase 2 and Phase 3 varenicline clinical trials that demonstrated its efficacy and tolerability have not included subjects with depression. This smoking cessation study focuses on the depressed population and will assess the efficacy and safety of varenicline.


Options:
A: Inclusion Criteria:

* Male or female cigarette smokers, 18-75 years, motivated to stop smoking and considered suitable for a smoking cessation attempt
* Smoked an average of at least 10 cigarettes per day during past year and over past month, and exhaled carbon monoxide (CO) \> 10 ppm at screening
* Current or past diagnosis of MDD without psychotic features, either single or recurrent, using DSM IV TR based on clinical assessment and confirmed by SCID and at least one of the following:
* On stable antidepressant treatment for MDD (stable dose for at least 2 months)
* Major depressive episode, using DSM IV TR, in the past 2 years successfully treated

Exclusion Criteria:

* Current or past diagnosis of dementia, schizophrenia, schizoaffective disorder, or other psychotic disorder, bipolar I disorder, bipolar II disorder.
* Subjects with antisocial, schizotypal, or any other personality disorder severe enough to compromise the subject's ability to comply with the study requirements..
* Current use of either bupropion or nortryptiline.
B: Inclusion Criteria:

* Outpatients over the legal age smoking at least 10 cigarettes per day for at least 2 months

Exclusion Criteria:

* Insufficient level of motivation
* Another participant in the household
* Patients with current psychotic disorder or major depressive disorder

The investigator will evaluate whether there are other reasons why a patient may not participate.
C: Inclusion Criteria:

* Smoked at least one puff in the past 7 days
* Confirmed viable gestation

Exclusion Criteria:

* All patients found to have a non-viable fetus or major congenital anomaly
* History of seizure disorder
* Family history of seizure disorder
* History of severe head trauma
* History of anorexia nervosa or bulimia
* Current use of nicotine-replacement therapy
* Unstable medical or psychiatric condition
* Current use of an monoamine oxidase inhibitor or bupropion hydrochloride products
D: Inclusion Criteria:

* Smoker seeking treatment
* Aged 18 and over
* Consenting to take part
* Report little or no change in enjoyment of cigarettes and/or nausea

Exclusion Criteria:

* Pregnant or breastfeeding
* Have severe kidney disease
* Have severe heart problems
* Have a current psychiatric illness
* Are unable to fill in questionnaires in English
* Have an allergy to varenicline
* Are currently involved in another clinical trial

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Evaluation of the Effect of Cranberry Capsules on the Occurrence of Urinary Tract Infections During Post-acute Rehabilitation of Spinal Cord Injured Patients
Brief Summary: The purpose of this study is to establish whether cranberry capsules reduce rates of urinary tract infections during initial rehabilitation immediately after spinal cord injury.


Options:
A: Inclusion Criteria:

* Recent confirmed urinary tract infection, diagnosed in Oulu University Hospital or Oulu Health Care Center
* Age 1-16 years

Exclusion Criteria:

* Continuous antimicrobial prophylaxis
* Age \< 12 months or \> 16 years
* Severe congenital kidney or other urinary tract anomaly in ultrasound
B: Inclusion Criteria:

1. Presenting at the gynecology clinic for a pre-operatory visit
2. Ability to give informed consent
3. Willing to take cranberry capsules for up to 6 weeks
4. 18 of age or older

Exclusion Criteria:

1. Pregnancy
2. History of nephrolithiasis
3. History of allergy to cranberry
4. Patient on anticoagulant medicine to be re-started during the 4-6 weeks after surgery
5. Less than 18 years old
C: Inclusion Criteria:

* Presenting with symptoms of UTI
* Presentation of 3rd or 4th simple cystitis of lower tract in the past 12 months
* Active infection at enrollment, confirmed and documented in medical record
* Cognitive capacity to consent and ability to undergo the consent process in English

Exclusion Criteria:

* Known allergy or intolerance to supplement ingredients
* Pregnant or planning to become pregnant or lactating
* Unwilling to commit to birth control use
* Use of related nutritional supplements
* Unwilling to halt berry extracts, polyphenols, antioxidants, d-mannose, vitamins
* Taken WelTract in past six months
* Unwilling to avoid probiotics, yogurt, apple or cranberry juice, hibiscus tea
* Certain comorbid or physical conditions
* History of febrile UTI
* Bladder catheter or urethral stents
* Use of topical hormones in urogenital areas
* Diabetes (i.e. taking diabetic medications) or glycosuria
* Intestinal diseases with malabsorption (e.g. Crohn's and celiac diseases)
* Severe renal impairment or kidney stones
* Neural problems (spinal cord injury or Multiple Sclerosis)
* Immunocompromised individuals
* Rheumatoid arthritis
* Lupus
* HIV
* Taking steroids or immunobiologic medications
* Prophylactic antibiotic use (e.g. post-coital)
* Other physician judgement
D: Inclusion Criteria:

1. Previously essentially healthy
2. Newly acquired spinal cord injury, T12 level or higher
3. Receiving in-patient care on the rehabilitation ward.
4. Expected admission duration \>= 4 weeks
5. 16 years old or older

Exclusion Criteria:

1. Current or previous disorder that increases the risk of urinary tract infection including diabetes, urological disorder, previous operation on urinary tracts or kidneys, immune dysfunction
2. Severe head injury with impairment of cognitive function
3. Allergy to cranberry
4. Renal failure
5. Warfarin (Coumarin) treatment with unstable INR
6. Current symptomatic urinary tract infection

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)
Brief Summary: This trial is conducted in Europe and in the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of NN1250 (insulin degludec) in subjects with type 1 diabetes.


Options:
A: Inclusion criteria:

- Paediatric patients diagnosed with T1DM aged at least 6 years to less than 18 years at screening.

Exclusion criteria:

* Treatment with oral or parenteral glucose-lowering medications other than insulin.
* HbA1c \< 7% or \> 12 % at screening.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
B: Inclusion Criteria:

* Insulin detemir naive
* Type 1 diabetes for at least 12 months
* HbA1c lesser than or equal to 11.0%

Exclusion Criteria:

* Significant concomitant diseases
C: Inclusion Criteria:

* Type 1 diabetes for 12 months or longer, hereof the last 3 months with injection based therapies
* Current treatment with any basal insulin (e.g. insulin glargine, insulin detemir, NPH insulin) using one or two daily injections and with three or more daily meal-time insulin injections (e.g. insulin aspart, insulin lispro, insulin glulisine, human insulin) used as bolus insulin therapy
* HbA1c maximum 10.0 % by central laboratory analysis
* Body Mass Index (BMI) below or equal to 35.0 kg/m\^2
* Ability to self-manage insulin therapy as assessed by confirmation (verbal confirmation at screening visit) of a changed insulin dose in the preceding two months prior to screening
* Ability and willingness to adhere to the protocol including performance of self measured plasma glucose (SMPG) profiles and self adjustment of insulin doses

Exclusion Criteria:

* Use within the last 3 months prior to Visit 1 of any antidiabetic glucose lowering drug other than insulin
* Cardiovascular disease, within the last 6 months prior to visit 1, defined as: stroke; decompensated heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty
* Uncontrolled treated/ untreated severe hypertension (systolic blood pressure above or equal to 180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure above or equal to 100 mmHg)
* Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures according to local requirements
* Cancer and medical history of cancer (except basal cell skin cancer or squamous cell skin cancer)
D: Participants originally enrolled in the Diabetes Control and Complications Trial (DCCT) (N01-DK-6-2204-A).

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Does Coffee Intake Reduce Postoperative Ileus After Elective Colectomy?
Brief Summary: The purpose of the investigators study is to investigate the effects of coffee on the return of bowel function and appetite, length of hospital stay, and complications after elective open colectomy in a prospective randomized trial. The primary efficacy endpoint is time to first bowel movement.


Options:
A: Inclusion Criteria:

* all gynecologic laparoscopic surgery
* normal level of CA 125 postmenopausal

Exclusion Criteria:

* loose teeth
* chronic obstipation
* laparotomy
* operations longer then 3 h
B: Inclusion Criteria:

* All out-patients \> 19 years old presenting for capsule endoscopy

Exclusion Criteria:

* Patients on narcotics
* Patients on motility enhancing and/or slowing drugs should stop these at least 5 days prior to the procedure or be excluded from the study.
* Patients, who have proven or suspected obstruction of the bowel.
* Patients, who have had prior small bowel and/or gastric surgery.
* Patients with an ileostomy.
* Patients who have a known and/or have a history of swallowing disorder
* Patients with diabetes and/or hypo-/hyper- thyroidism
* Patients in whom the capsule become impacted at a stricture (these patients will be taken out of the study and given the necessary medical/surgical treatment).
C: Inclusion Criteria:

* Patients scheduled for elective open or laparoscopic colectomy
* Age equal or greater than 18 years
* Informed consent

Exclusion Criteria:

* Participation in concurrent intervention trials
* Need for a stoma
* Known hypersensitivity or allergy to coffee
* Expected lack of compliance
* Impaired mental state or language problems
* change in surgical procedure
D: Inclusion Criteria:

* Patients underwent abdominal surgery for non neoplastic diseases

Exclusion Criteria:

* Metastatic disease
* History of inflammatory bowel disease
* Postoperative fever
* Gastrointestinal fistula
* Mint or olive allergy; and/or
* Earlier abdominal radiation

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Randomized Controlled Trial Comparing Conventional and Fast Track Multi-Discipline Treatment Interventions for Colorectal Cancer
Brief Summary: A new notion"Fast Track Multi-Discipline Treatment" for colorectal cancer is thought with several benefits such as shorter hospitalization stay and less costs. This randomized study aims to compare the differences between conventional and Fast Track Multi-Discipline Treatment for colorectal cancer in hospitalization day, complications, costs and quality of life.


Options:
A: Inclusion Criteria:

* 18 years or more
* Advanced ovarian cancer ( FIGO Stages III-IV, and relapses) tributary to laparotomic surgical management.
* Patient accepts participation in the study and signs informed consent.

Exclusion Criteria:

* ASA IV
* Active ischemic cardiac condition
* Advanced cirrhosis ( Child-Pugh B -C).
* Severe Psychiatric condition ( patient not capable of giving her informed consent properly, not capable or not willing to attend Follow-up visits).
B: Inclusion Criteria:

1. Patients with pathologically confirmed colorectal cancer
2. Signed consent

Exclusion Criteria:

1. Tumor can be resected by endoscopic mucosal resection(EMR)
2. History of malignancy
3. Bowel obstruction or intestinal perforation
4. Evidence of metastasis by physical examination, chest roentgenogram and computed tomography of liver and pelvis
5. Acute diseases and acute attack of chronic diseases
6. Psychiatric history
7. Deformity of spine
8. ASA score≥Ⅳ
9. Mid-low rectal cancer
10. Pregnant woman
11. Needing to use Chinese traditional patent drug
C: Inclusion Criteria:

* Age \>18 and \<75 years old
* Patients candidated for elective gynecological surgery for benign pathology
* Patients with diagnosis of gynecological neoplasm and candidated for elective gynecological surgery
* Signed consent form
* Karnofsky Performance Status \> 70

Exclusion Criteria:

* ASA score \> 3
* Contraindication to loco-regional anaesthesia
* Patients with ileus or subocclusive condition prior surgery
* Coagulation disorders
* Organ failure or severe disfunction (heart, renal, pulmonary, hepatic)
* Uncontrolled hypertension (\>180/95)
* Alcohol or drug abuser (current or previous)
* Unability to self-care (PFS \< 70)
* Comorbidity-Polypharmacy Score \> 22
* Psychiatric condition or language barriers
* Planned Intensive Care Recovery
D: Inclusion Criteria:

1. Patients scheduled for gynecological oncology surgery(including radical hysterectomy add lymphadenectomy, hysterectomy add lymphadenectomy and cytoreductive)
2. Aged 18 years or older
3. Signed informed consent provided

Exclusion Criteria:

1. Patients with a documented infection at the time of operation
2. Aged 71 years or older
3. Patients with ileus at the time of operation
4. Patients with hypocoagulability
5. Patients with psychosis, Alcohol dependence or drug abuse history
6. Patients with primary nephrotic or hepatic disease
7. Patients with severe hypertension systolic pressure≥160mmHg, diastolic pressure\>90mmHg

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Assertive Community Treatment (ACT) as Part of Integrated Care Versus Standard Care: a 12-month Trial in Patients With First- and Negatively Selected Multiple-episode Schizophrenia-spectrum Disorders Treated With Quetiapine IR
Brief Summary: The study examined the 12-month effectiveness of continuous therapeutic assertive community treatment (ACT) as part of integrated care (IC) compared to standard care (SC) in a catchment area comparison design in patients with schizophrenia spectrum disorders (SSD) treated with quetiapine IR.


Options:
A: Inclusion Criteria:

* Must be English speaking
* 75 years of age and over
* Newly referred to and eligible for personal support services
* Living at home in the community
* Identified as being at risk for falls

Exclusion Criteria:

* Refusal to give informed consent
* Unable to read/write English and a translator is not available
B: Inclusion Criteria:

* Age 18-65 years
* Met the diagnostic criteria of a first- or multiple episode of a schizophrenia spectrum disorders, i.e. schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, or psychotic disorder NOS
* New initiation or current treatment with quetiapine Immediate Release (IR)

Exclusion Criteria:

* Other psychotic disorders (e.g., due to medical condition)
* Mental retardation (IQ lower than 70 points)
C: Inclusion Criteria:

* enrolled in participating school district in grades 1-5.

Exclusion Criteria:

* None
D: Inclusion Criteria:

* Aged 14 years and over on 1st Jan 1999
* About to enter year 5, 6 or 7 of a primary school in one of the 20 trial communities

Exclusion Criteria:

\* Parent/guardian and/or young person unable or unwilling to give informed consent

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Exercising With Computers in Later Life (EXCELL) - Pilot and Feasibility Study of the Nintendo® WiiFit in Community-dwelling Fallers
Brief Summary: This is a pilot study to assess whether balance training with the Nintendo® Wii is comparable to a physiotherapist-led falls group in terms of improvement in balance. The acceptability of the Nintendo® Wii will also be assessed.


Options:
A: Inclusion Criteria:

* age 70 years or older
* living locally in the community (in either sheltered accommodation or own home
* fallen at least once in the preceding 12 months
* abbreviated mental test (AMT) of seven or over

Exclusion Criteria:

* wheelchair bound
* people living in a care home or long-term hospital care.
B: Inclusion Criteria:

* Sedentary (less than twice weekly exercising) women aged 65-75 years old without conditions restricting them from exercising.
C: Inclusion Criteria:

* age: 65-85 years
* Mini-Mental State Examination (MMSE) score \> 24
* English-speaking with the ability to understand the nature of the study and provide informed consent
* independent in ambulatory functions, with or without an assistive device (cane or walker).

Exclusion Criteria:

* any medical condition or disability that prevented participation in an exercise program.
D: Inclusion Criteria:

* 65 years old or older
* Having been treated in emergency department or submitted to hospital after a fall
* Living in the Glostrup area.

Exclusion Criteria:

* Fall due to strong external force, new apoplexia cerebri, epileptic seizure, alcohol intoxication.
* Known cognitive impairment
* Not able to walk prior to fall
* Living in institution
* Planned geriatric intervention.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Solar Disinfection of Drinking Water for Use in Developing Countries or in Emergency Situations
Brief Summary: SODISWATER is a European Union funded health impact assessment study investigating the effect of sunlight to inactivate microbial pathogens in drinking water. This study was done by observing whether children younger than 5 years old who drink solar disinfected water were healthier than those who did not. Health was measured by how often the children had diarrhoea.

Participants were given plastic bottles to place in the sun, water samples were then collected from these plastic bottles to be analyzed. They were also requested to fill in diarrhea diaries.

TESTABLE RESEARCH HYPOTHESES:

Health Impact Assessment: Children who use solar disinfected water will have:

(a) lower morbidity due to non-bloody diarrhoea and bloody diarrhoea (c) increased growth rates (d) lower mortality (e) increased family productivity (f) decreased care-giver burden (g) increased school attendance


Options:
A: Inclusion Criteria:

* All children under five years of age in the randomly selected clusters of Kersa district

Exclusion Criteria:

* seriously sick children in the randomly selected clusters of Kersa district
B: Inclusion Criteria:

* All households in three selected villages

Exclusion Criteria:

* None
C: Inclusion Criteria:

(1) Infants (target child) will be eligible to participate in the study if they are:

1. They are in utero at the baseline survey
2. Their parents/guardians are planning to stay in the study village for the next 12 months (if a mother is planning to give birth at her natal home and then return, she will still be a candidate for enrollment)

(2) Children \< 36 months old at baseline that are living in the compound of a target child will be eligible to participate in diarrhea measurement if:

1. They are \< 36 months old at the baseline survey
2. Their parents/guardians are planning to stay in the study village for the next 12 months

(3) Children 18 - 27 months old at baseline that are living in the compound of a target child will be eligible to participate in intestinal parasite specimen collection if:

1. They are 18 - 27 months old at the baseline survey
2. Their parents/guardians are planning to stay in the study village for the next 12 months
D: Inclusion Criteria:

* Presence of one or more children aged less than 5 years in the household

Answer: D